Digest Network Come funziona
Network
/
Società
Ka
Non verificato

KalVista Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

74 comunicati stampa

Guarda tutti i comunicati
10/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Eventi
Industria
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Web e Social Network
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/10/2025
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/10/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/10/2025
Biotecnologia
Salute
Scienza
Farmaceutica
Mercato del lavoro
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/09/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/09/2025
Titoli e azioni
Biotecnologia
Salute
Scienza
Farmaceutica
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0